CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02523196
NCT02523196Phase 3Completed
CompareCT.gov

Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)

University of Colorado, Denver·interventional·Posted Aug 14, 2015·Updated Aug 9, 2021

In Brief

A Phase 3 clinical trial evaluating HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate) and Hepatic Venous Pressure Gradient (HVPG) for Liver Disease. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study plans to learn more about a new test to look at liver function, the HepQuant-Shunt (HQ-Shunt). The HQ-Shunt is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient testing in patients with liver disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Disease
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 14, 2015
Enrollment StartMar 1, 2016
Primary CompletionFeb 23, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.9 years ago

Interventions

HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)drug

The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease

Hepatic Venous Pressure Gradient (HVPG)device

Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease